Cancer gene and oncolytic virus therapy

Seminars in Oncology

Volumn 28, Issue 4, 2001, Pages 336-343

  Zwiebel, James A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ONCOLYTIC VIRUS; PRODRUG; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CELL DESTRUCTION; CELL DIVISION; CYTOTOXICITY; DNA MODIFICATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HERPES VIRUS; IMMUNITY; IMMUNOTHERAPY; MARKER GENE; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; REOVIRUS; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0034889728     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90128-9     Document Type: Article

References (67)

1. Gene therapy strategies for carcinoma of the breast
2. Molecular chemotherapy for breast cancer
3. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
4. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
5. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
6. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer
7. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy
8. Three phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (AD5CMV-P53) in patients with recurrent/refractory head and neck cancer
9. Phase I dose escalation trial of intravenous (IV) infusion of Onyx-015 in patients with refractory cancer
10. The next frontier of molecular medicine: Delivery of therapeutics
11. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth
12. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
13. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA 4Ig administration
14. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA 4Ig
15. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
16. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
17. Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer
18. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
19. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide
20. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
21. Strategies to adapt adenoviral vectors for targeted delivery
22. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts
23. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells
24. 1-integrin-displaying cells by a synthetic peptide
25. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
26. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
27. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
28. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
29. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
30. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
31. Actions of HSVtk and connexin43 gene delivery on gap junctional communication and drug sensitization in hepatocellular carcinoma
32. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
33. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
34. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
35. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
36. Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect"
37. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer
38. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: The Good Samaritan effect
39. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7
40. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy
41. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy
42. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy
43. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions
44. Enzyme prodrug gene therapy: Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer
45. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
46. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes
47. Recombinant interferon α2a synergistically enhances ganciclovir-mediated tumor cell killing in the herpes simplex virus thymidine kinase system
48. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
49. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
50. ON-YX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
51. A phase II trial of ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
52. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
53. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
54. Molecular and clinical activity of CN706, a PSA selective oncolytic Ad5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy
55. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1
56. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
57. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
58. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
59. Reovirus as a novel oncolytic agent
60. Immunization with virus-modified tumor cells
61. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
62. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy
63. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically, modified strain of Salmonella typhimurium
64. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
65. Parvoviral vectors for the gene therapy of cancer
66. Intergeneric poliovirus recombinants for the treatment of malignant glioma